X-Therma Inc. raised $22.4M in a Series B funding round led by Starling Locke Capital to scale global commercial operations and advance key products for regenerative medicine and organ preservation.
X-Therma Inc. raised $22.4M in a Series B funding round led by Starling Locke Capital to scale global commercial operations and advance key products for regenerative medicine and organ preservation.
03/13/24, 7:30 PM
Location
richmondMoney raised
$22.4 million
Investors
Lorea Ag, Starling Locke Capital
X-Therma Inc. completed an oversubscribed $22.4 million Series B funding round to scale global commercial operations and advance key products in regenerative medicine and organ preservation. The investment enables the company's progression to the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations.
Company Info
Location
625 alfred nobel drive suite b
richmond, california, united states
Additional Info
X-Therma is headquartered in Richmond, part of the San Francisco Bay Area, with research centers in Richmond and Berkeley, and now has expanded to Europe in Austria. X-Therma pioneers ground-breaking cold chain technology via a convergent biopreservation platform, to advance Regenerative Medicine and make available safe and on-demand organs, engineered tissues, cell & gene therapies, vaccines, and beyond to patients in need. X-Therma’s technology could be a paradigm shift that makes worldwide organ sharing possible and eliminates organ waiting lists across the globe. X-Therma has been a selected Industrial User at the Lawrence Berkeley National Laboratory and received over $10M contracts and grant support from the U.S. Department of Defense, the National Science Foundation, and the California Institute for Regenerative Medicine.